The neuropeptides calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-
activating polypeptide (PACAP) have emerged as mediators of migraine pathogenesis. Both …

Background Migraine is a disabling and chronic neurovascular headache disorder.
Trigeminal vascular activation and release of calcitonin gene-related peptide (CGRP) play a …

Calcitonin gene-related peptide (CGRP)-antagonizing drugs represent a major advance in
migraine treatment. However, up to 50% of patients do not benefit from monoclonal …

There are several endogenous molecules that can trigger migraine attacks when
administered to humans. Notably, calcitonin gene-related peptide (CGRP) has been …

We aimed to investigate a sexually dimorphic role of calcitonin gene-related peptide (CGRP)
in rodent models of pain. Based on findings in migraine where CGRP has a preferential pain …

Migraine is a widespread and debilitating neurological condition affecting more than a
billion people worldwide. Thus, more effective migraine therapies are highly needed. In the …

Background Chronic migraine is a common and highly disabling disorder. Functional MRI
has indicated that abnormal brain region activation is linked with chronic migraine. Drugs …

Globally, migraine is a leading cause of disability with a huge impact on both the work and
private life of affected persons. To overcome the societal migraine burden, better treatment …

Preclinical data point to the contribution of transient receptor potential ankyrin 1 (TRPA1)
channels to the complex mechanisms underlying migraine pain. TRPA1 channels are …

Migraine is one of the leading causes of disability worldwide, affecting work and social life. It
has been estimated that sales of migraine medicines will reach 12.9 billion USD in 2027. To …